SkinBioTherapeutics Financials
| SBTX Stock | 15.88 0.37 2.28% |
Operating Margin (13.01) | EPS Estimate Current Year (0.01) | Return On Equity (1.19) |
SkinBioTherapeutics | Select Account or Indicator |
Understanding current and past SkinBioTherapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of SkinBioTherapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in SkinBioTherapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in SkinBioTherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SkinBioTherapeutics PLC. Check SkinBioTherapeutics' Beneish M Score to see the likelihood of SkinBioTherapeutics' management manipulating its earnings.
SkinBioTherapeutics Stock Summary
SkinBioTherapeutics competes with Taylor Maritime, Bankers Investment, X FAB, Alfa Financial, and Ashtead Technology. SkinBioTherapeutics is entity of United Kingdom. It is traded as Stock on LSE exchange.| Foreign Associate | USA |
Specialization | Consumer Staples, Household & Personal Products |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| ISIN | GB00BF33H870 |
| Business Address | The Core, Newcastle |
| Sector | Personal Care Products |
| Industry | Consumer Staples |
| Benchmark | Dow Jones Industrial |
| Website | www.skinbiotherapeutics.com |
| Phone | 44 19 1495 7325 |
You should never invest in SkinBioTherapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of SkinBioTherapeutics Stock, because this is throwing your money away. Analyzing the key information contained in SkinBioTherapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
SkinBioTherapeutics Key Financial Ratios
There are many critical financial ratios that SkinBioTherapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that SkinBioTherapeutics PLC reports annually and quarterly.| Revenue | 132.06 K | ||||
| Gross Profit | 45.34 K | ||||
| EBITDA | (2.96 M) | ||||
| Net Income | (2.84 M) | ||||
| Total Asset | 2.59 M |
SkinBioTherapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 2.8M | 5.7M | 3.1M | 2.6M | 3.0M | 3.6M | |
| Other Current Liab | 150.7K | 283.3K | 345.5K | 241.1K | 277.3K | 173.5K | |
| Net Tangible Assets | 3.5M | 2.0M | 4.7M | 2.1M | 2.4M | 3.1M | |
| Net Debt | (2.2M) | (4.5M) | (1.7M) | (1.2M) | (1.4M) | (1.5M) | |
| Retained Earnings | (4.1M) | (5.5M) | (8.3M) | (11.1M) | (10.0M) | (9.5M) | |
| Accounts Payable | 138.6K | 78.8K | 72.6K | 194.3K | 223.4K | 234.6K | |
| Cash | 2.2M | 4.6M | 1.8M | 1.3M | 1.5M | 2.8M | |
| Net Receivables | 141.4K | 213.4K | 1.8K | 816.0 | 734.4 | 697.68 | |
| Inventory | (141.4K) | (213.4K) | 122.6K | 33.5K | 38.5K | 40.4K | |
| Other Current Assets | 189.4K | 452.8K | 403.3K | 374.6K | 430.8K | 312.6K | |
| Total Liab | 304.8K | 519.7K | 609.6K | 599.3K | 689.2K | 346.0K | |
| Total Current Assets | 2.3M | 5.1M | 2.3M | 1.7M | 2.0M | 3.1M | |
| Intangible Assets | 420.5K | 528.9K | 625.5K | 700.3K | 805.4K | 448.5K | |
| Net Invested Capital | 2.5M | 5.2M | 2.7M | 2.0M | 1.8M | 2.7M | |
| Net Working Capital | 2.0M | 4.7M | 2.1M | 1.2M | 1.1M | 1.0M |
SkinBioTherapeutics Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Gross Profit | (5.1K) | (5.1K) | 15.9K | 85.2K | 98.0K | 102.9K | |
| Operating Income | (1.6M) | (1.5M) | (3.0M) | (3.0M) | (2.7M) | (2.6M) | |
| Ebit | (1.6M) | (1.5M) | (3.0M) | (3.0M) | (2.7M) | (2.6M) | |
| Research Development | 635.2K | 505.6K | 861.4K | 930.6K | 1.1M | 579.5K | |
| Ebitda | (1.6M) | (1.5M) | (3.0M) | (3.0M) | (2.7M) | (2.5M) | |
| Cost Of Revenue | 5.1K | 5.1K | 58.8K | 46.9K | 53.9K | 56.6K | |
| Income Before Tax | (1.6M) | (1.5M) | (3.0M) | (3.0M) | (2.7M) | (2.6M) | |
| Net Income | (1.5M) | (1.4M) | (2.8M) | (2.8M) | (2.6M) | (2.4M) | |
| Income Tax Expense | (120.0K) | (65.1K) | (199.6K) | (173.1K) | (155.8K) | (163.6K) | |
| Tax Provision | (120.0K) | (65.1K) | (199.6K) | (174.1K) | (156.7K) | (164.5K) |
SkinBioTherapeutics Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (965.8K) | 2.5M | (2.8M) | (493.1K) | (443.8K) | (421.6K) | |
| Free Cash Flow | (965.8K) | (1.7M) | (2.8M) | (2.8M) | (2.5M) | (2.4M) | |
| Depreciation | 5.1K | 5.1K | 29.7K | 44.2K | 50.8K | 53.4K | |
| Other Non Cash Items | 85.6K | 204.6K | (71.1K) | 131.6K | 151.4K | 158.9K | |
| Capital Expenditures | 73.7K | 112.3K | 96.8K | 165.3K | 190.1K | 102.6K | |
| Net Income | (1.5M) | (1.4M) | (2.8M) | (2.8M) | (2.6M) | (2.4M) | |
| End Period Cash Flow | 2.2M | 4.6M | 1.8M | 1.3M | 1.5M | 2.8M | |
| Change To Netincome | (46.8K) | 247.4K | (3.8K) | (30.4K) | (27.3K) | (26.0K) | |
| Investments | (73.7K) | (112.3K) | (96.8K) | (165.3K) | (148.7K) | (156.2K) |
SkinBioTherapeutics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SkinBioTherapeutics's current stock value. Our valuation model uses many indicators to compare SkinBioTherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SkinBioTherapeutics competition to find correlations between indicators driving SkinBioTherapeutics's intrinsic value. More Info.SkinBioTherapeutics PLC is rated second in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SkinBioTherapeutics' earnings, one of the primary drivers of an investment's value.SkinBioTherapeutics PLC Systematic Risk
SkinBioTherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. SkinBioTherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on SkinBioTherapeutics PLC correlated with the market. If Beta is less than 0 SkinBioTherapeutics generally moves in the opposite direction as compared to the market. If SkinBioTherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one SkinBioTherapeutics PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of SkinBioTherapeutics is generally in the same direction as the market. If Beta > 1 SkinBioTherapeutics moves generally in the same direction as, but more than the movement of the benchmark.
SkinBioTherapeutics PLC Total Assets Over Time
SkinBioTherapeutics November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of SkinBioTherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of SkinBioTherapeutics PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of SkinBioTherapeutics PLC based on widely used predictive technical indicators. In general, we focus on analyzing SkinBioTherapeutics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build SkinBioTherapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.33 | |||
| Information Ratio | 0.0847 | |||
| Maximum Drawdown | 21.17 | |||
| Value At Risk | (5.94) | |||
| Potential Upside | 9.68 |
Additional Tools for SkinBioTherapeutics Stock Analysis
When running SkinBioTherapeutics' price analysis, check to measure SkinBioTherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SkinBioTherapeutics is operating at the current time. Most of SkinBioTherapeutics' value examination focuses on studying past and present price action to predict the probability of SkinBioTherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SkinBioTherapeutics' price. Additionally, you may evaluate how the addition of SkinBioTherapeutics to your portfolios can decrease your overall portfolio volatility.